Source: University of Pittsburgh From: eurekalert.org Oncologists faced with treating older women with breast cancer often must decide if the treatment may be more detrimental than the cancer. A study published today in JAMA Network Open by researchers at UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine sheds new light on this choice and suggests the …
An Inspired Breast Cancer Survivor Becomes the Inspiring One
View PostAddition of SDX-7320 to Palbociclib Inhibits Tumor Growth in Breast Cancer Xenografts
By: Hayley Virgil From: onclive.com The addition of SDX-7320, a novel inhibitor of methionine aminopeptidase 2 (MetAP2), to palbociclib (Ibrance) was found to inhibit MCF-7 tumor growth and reduce the expression of proteins associated with resistance to palbociclib, according to data from a study virtually presented during the AACR Annual Meeting 2021.1 Results indicated that SDX-7320 and palbociclib, when given …
Breast Cancer Patients Needing Radiation Therapy Face Higher Risk of Implant Reconstruction Complications Requiring Additional Surgery
From: breastadvocateapp.com Implant-based breast reconstruction is the most commonly performed method of reconstruction in the United States today. While the procedure can be performed in one surgery (known as ‘direct to implant’), most women have a 2-stage approach beginning with tissue expanders. These are replaced with a permanent implant a few months later at a second surgery (stage 2) Implants …
Contrast-Enhanced Mammography Useful in Women with Breast Implants
By: Whitney J. Palmer From: diagnosticimaging.com CEM performance showed no significant difference between women with or without breast implants, and it produced very few complications. Contrast-enhanced mammography (CEM) is an acceptable alternative to breast MRI for women who have breast implants, according to recently presented research. CEM has already been shown to be an effective diagnostic or screening option for …
Therapeutic cancer vaccine shows promise against multiple tumor types
By: Dennis Thompson From: medicalxpress.com Marc Baum went through all the usual steps to treat his bladder cancer—a couple of surgeries, radiation therapy and chemotherapy, all in a three-month period. But doctors hope that an extra step—an experimental vaccine—will be what keeps Baum’s cancer from coming back. A vaccine that uses genetics to teach a person’s immune system how to …
Gedatolisib Plus Palbociclib Shows Promise in Treating ER+/HER2- Advanced Breast Cancer
By: Sara Karlovitch From: targetedonc.com Gedatolisib, a first-in-class PI3K/mTOR inhibitor, plus palbociclib and endocrine therapy demonstrated tolerability and preliminary efficacy in patients with ER+/HER2- advanced or metastatic breast cancer. Gedatolisib, a first-in-class PI3K/mTOR inhibitor, plus palbociclib (Ibrance) and endocrine therapy demonstrated tolerability and preliminary efficacy in patients with ER+/HER2- advanced or metastatic breast cancer, according to early results on a …
New potential breast cancer drug identified
By: PTI From: telanganatoday.com Scientists, including an Indian-American researcher, have identified a molecule that can help treat breast cancer, giving hope to patients who have become resistant to traditional therapies. The first-in-class molecule shuts down oestrogen-sensitive breast cancer in a new way, researchers said. First-in-class drugs are those that work by a unique mechanism – in this case a molecule …
First-Line Palbociclib/Letrozole Shows Real-World Survival Benefit in HR+ Metastatic Breast Cancer
By: Kristi Rosa From: onclive.com Palbociclib in combination with endocrine therapy resulted in improved survival outcomes in a real-world population of patients with hormone receptor–positive, HER2-negative, metastatic breast cancer vs letrozole alone in the first-line setting. Palbociclib (Ibrance) in combination with endocrine therapy resulted in improved survival outcomes in a real-world population of patients with hormone receptor (HR)–positive, HER2-negative, metastatic …
Real-World Evidence Supports Efficacy of Palbociclib Plus Letrozole in HR+/HER2– Breast Cancer
By: Audrey Sternberg From: cancernetwork.com An analysis of real-world outcomes in a cohort of patients treated in mostly community settings showed that palbociclib plus letrozole improved both progression-free and overall survival in women with hormone receptor–positive, HER2-negative metastatic breast cancer. Data published in Breast Cancer Research showed real-world efficacy of palbociclib (Ibrance) in combination with letrozole in women with hormone …